Chester County News and Community Website
PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate cancer. …
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives Read More PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) has recognized several individuals and contributors with its 2025 awards, celebrating their remarkable commitment to quality, equitable, and accessible cancer …
NCCN Honors Leaders Advancing Cancer Care with 2025 Awards Read More
WILMINGTON, DE — A new treatment option has emerged for patients battling advanced squamous cell carcinoma of the anal canal (SCAC). The U.S. Food and Drug Administration (FDA) has approved …
FDA Approves Zynyz for Advanced Anal Cancer, Offering New Hope for Patients Read More
NEWTOWN SQUARE, PA and SHANGHAI, CHINA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced an exclusive license agreement with Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) for global rights outside Greater …
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent in Japan for its aPKCi inhibitor platform, a potential breakthrough in treating hedgehog pathway-dependent cancers. …
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. This experimental treatment is a …
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy Read More
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its proprietary Ac-EBTATE radiopharmaceutical, demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small …
Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer Treatment Read More
PHILADELPHIA, PA — The Wistar Institute has unveiled a groundbreaking approach to tackling ovarian cancer, potentially revolutionizing treatment outcomes for the deadliest of gynecological cancers. Led by Nan Zhang, Ph.D., …
Pioneering Discovery by The Wistar Institute Offers New Hope in Ovarian Cancer Treatment Read More
BERWYN, PA — Panavance Therapeutics Inc. has announced groundbreaking findings this week, demonstrating the potential of their investigational drug, misetionamide (GP-2250), to tackle various forms of cancer by directly inhibiting …
Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), in collaboration with Moderna, Inc. (Nasdaq: MRNA), has announced promising pre-clinical results for their innovative anti-GPC3 chimeric antigen receptor macrophage (CAR-M) therapy targeting …
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy Read More